Virtual Access Only | TBD CE/CME Credits & MOC Points
The Best of Breast Conference will take place on February 22, 2025. This innovative and state of the art hybrid program was set in a multidisciplinary tumor board environment featuring some of the world's leading breast cancer experts to discuss cases beginning with high-risk characteristics, adjuvant and metastatic treatment advances, interdisciplinary care, and survivorship and recurrence—all while incorporating data from the major oncologic annual meetings.
Conference Agenda
Saturday, February 22, 2025
8:00 AM
Coffee and Exhibits
8:30 AM
Targeted Therapies in HER2+ Breast Cancer: Current and Emerging Options
8:42 AMCDK4/6 Inhibitors in HR+/HER2- Breast Cancer: Latest Advances
CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: Latest Advances
8:54 AM
PARP Inhibitors in BRCA-Mutated Breast Cancer: Evolving Strategies
9:06 AM
Innovative Diagnostic Tools: Role of ctDNA in Early Detection and Monitoring
9:18 AM
Breakfast and Exhibits
9:33 AM
Non-CME Breakfast
10:18 AM
Management of Triple-Negative Breast Cancer (TNBC): Immunotherapy and Beyond
10:30 AM
Adjuvant Therapy in Early-Stage ER+/HER2- Breast Cancer: Best Practices
10:42 AM
Updates on Neoadjuvant Therapy: Optimizing Outcomes in Breast Cancer
10:54 AM
Personalizing Therapy in Metastatic Breast Cancer: A Case-Based Approach
11:06 AM
Genomic Profiling and the Future of Breast Cancer Treatment
11:18 AM
Lunch and Exhibits
11:33 AM
Non-CME Lunch
12:18 PM
Novel Approaches in HER2-Low Breast Cancer: Changing Paradigms
12:30 PM
The Role of mTOR Inhibitors in Advanced Breast Cancer
12:42 PM
Managing Bone Health in Breast Cancer Patients on Long-term Therapy
12:54 PM
Break and Exhibits
1:04 PM
Strategies for Managing Treatment-Related Toxicities in Breast Cancer
1:16 PM
Breast Cancer in Young Women: Unique Challenges and Treatment Approaches
1:28 PM
Addressing Disparities in Breast Cancer Outcomes
1:40 PM
Extended Panel Discussion: Integrating Emerging Therapies into Clinical Practice
3:30 PM
Adjourn
Agenda Subject To Change. All times are EST.
-
Apply the current standards of oncology care and key updates from national clinical guidance pathways to optimize the management of patients with various breast cancers.
Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with breast cancer.
Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with breast cancer.
-
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of TBD ANCC contact hours.
Physicians (ACCME) Credit Designation
Amedco LLC designates this live activity for a maximum of TBD AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists and Pharmacy Technicians (ACPE) Credit Designation
Amedco LLC designates this activity for a maximum of TBD knowledge-based CPE contact hours.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
-
Free registration for all healthcare providers
Expert sessions that present the most clinically relevant data, research, and clinical strategies
Real-time discussion and debate
Networking with peers, colleagues, and medical professionals
Access to the latest industry information and resources
Catered meals through-out the program